Replies to post #57008 on Biotech Values

[DewDiligence]

>Dew, the last update I remember to your “HCV: Most Likely to Succeed“ list came after the 9-21-07 MAXY-ALPHA hold announcement. Given VRTX’s problems with Telaprevir (see below), are you going to issue an update?<

The latest list is in #msg-23085478. I don’t think an update is warranted just because a sell-side analyst downgraded VRTX.

Telaprevir is still the most likely HCV drug candidate to succeed, IMO. Regards, Dew

[ThomasS]

"Given VRTX’s problems with Telaprevir"
--A Wachovia analyst's comments do not make or break drug development...

EDIT: I see Dew stated as much.

[justrpaul]

Wachovia is a market maker in Vertex stock. They are thus able to 'naked short' and they generally profit more as a market maker when trading volume is higher. Since, the Wachovia analyst made his recent comments roughly two months after AASLD, one can reasonably wonder wheter he has any real new news on which to base his comments, or he just feels an incentive to help Wachovia profit a little in the face of their mammoth sub-prime losses.